Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Opus Secures $1.7M Funding from Foundation Fighting Blindness
Opus Genetics, a pioneering gene therapy company focused on inherited retinal diseases, has secured $1.7 million in project-based funding from the Foundation Fighting Blindness. This financial support aims to accelerate the development of two preclinical candidate programs critical for advancing…
FDA Grants Breakthrough and RMAT Status to Aurion’s AURN001
Aurion Biotech has been granted Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) Designation by the FDA for AURN001, Aurion’s innovative allogeneic cell therapy candidate designed to treat corneal edema secondary to corneal endothelial disease. Expediting Development and…
RevOpsis and Kemwell Form Manufacturing Partnership for nAMD
RevOpsis Therapeutics and Kemwell Biopharma have forged a strategic manufacturing partnership aimed at accelerating the development of RO-104, a pioneering tri-specific biologic designed by RevOpsis for treating neovascular age-related macular degeneration (nAMD). Neovascular age-related macular degeneration (nAMD) is a progressive…
Oculis’ Licaminlimab Shows Promise in Phase 2B Trial for DED
Oculis Holding announced positive topline results from its phase 2b RELIEF trial, shedding light on the efficacy of licaminlimab, an innovative anti-TNFα biologic eye drop, in addressing dry eye disease (DED). Licaminlimab’s established dual mechanism of action, boasting both anti-inflammatory…
Study Identifies Risk Factors for Hydroxychloroquine Retinopathy
A recent study published online in JAMA Network Open sheds light on factors associated with an increased risk for hydroxychloroquine retinopathy. The research, led by April M. Jorge, M.D., from Massachusetts General Hospital in Boston, identifies crucial risk factors beyond…
What is X-Linked Retinitis Pigmentosa
Retinitis pigmentosa (RP) describes a group of rare genetic eye diseases that damage light-sensitive cells in the retina, leading to loss of sight over time. In about 10% of RP cases, the non-working gene is passed down from the mother…
Metformin Found Ineffective Against Geographic Atrophy
In the quest to find effective treatments for eye diseases, the METformin for the MINimization of Geographic Atrophy Progression (METforMIN) trial sought to evaluate the efficacy of oral metformin in slowing the progression of geographic atrophy (GA) and its effects…
Preseptal and Orbital Cellulitis | OBN
Preseptal cellulitis (periorbital cellulitis) is infection of the eyelid and surrounding skin anterior to the orbital septum. Orbital cellulitis is infection of the orbital tissues posterior to the orbital septum. Either can be caused by an external focus of infection (eg, a wound),…
Nordic Pharma Introduces Lacrifill Canalicular Gel for Dry Eye
Nordic Pharma announced the commercial launch of Lacrifill Canalicular Gel, aimed at addressing dry eye disease in the United States. This novel therapy, Lacrifill, is a cross-linked hyaluronic acid derivative that has received clearance from the FDA. Its primary function…
J&J’s Nipocalimab Shows Promising Results in Sjögren’s Disease
Johnson & Johnson announced promising topline results from its Phase 3 VIVACITY study evaluating nipocalimab in adults with generalized myasthenia gravis (gMG), alongside findings from the Phase 2 DAHLIAS study in adults with Sjögren’s disease (SjD). Nipocalimab, an investigational treatment,…